Praelolide, a potent Nrf2 activator, disrupts Keap1-Nrf2 protein-protein interactions through noncovalent binding to Keap1, inhibiting osteoclastogenesis and the production of reactive oxygen species (ROS). With its potential in osteoclastogenic bone disease research, Praelolide presents a promising avenue for therapeutic exploration.